Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.
Barendrecht
Maurits M
MM
Department of Pharmacology, University of Amsterdam, Amsterdam, the Netherlands.
Koopmans
Richard P
RP
de la Rosette
Jean J M C H
JJ
Michel
Martin C
MC
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012307:Risk Factors
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors